The adoption of robotic pancreatoduodenectomy (RPD) is gaining momentum; however, its impact on major outcomes, including pancreatic fistula, has yet to be adequately compared with open pancreatoduodenectomy (OPD).
plication to pancreatoduodenectomy (PD), however, has thus far been tempered for a number of reasons, including concerns regarding oncologic effectiveness, cost control, training issues, and technical challenges associated with the operation. 8 Some of the technical drawbacks associated with laparoscopic approaches for PD may be ameliorated through robotic techniques, which offer 3-dimensional vision and advanced degrees of freedom and stability in tool handling. 8 Some propose that this added precision can improve the execution of the reconstruction aspect of PD, particularly for the detailed creation of the pancreatic or biliary anastomoses.
The most common and morbid complication following PD is postoperative pancreatic fistula.
9-12 Clinically relevant pancreatic fistulas (CR-POPFs) (International Study Group of Pancreatic Fistula [ISGPF] grades B and C
13
) significantly alter the patient's optimal recovery pathway and account for more than one-third of mortalities following PD.
14,15 Since most robotic PDs (RPDs) are currently performed in select centers by specialized surgeons, comparative analyses of CR-POPF occurrence between robotic and open approaches have been limited to small, single-center retrospective cohort studies of variable quality. [16] [17] [18] [19] These studies have been unable to detect significant differences in CR-POPF occurrence between operative approaches; however, each study has been underpowered (< 50 RPDs), and robotic cases were often limited to specific subsets of selected patients. Propensity score matching offers a method to minimize bias from nonrandomized treatment assignment and enables impartial comparisons of cohorts, which otherwise cannot be assessed in a randomized fashion. Applying this concept to the present study, the propensity score is a patient's probability of undergoing RPD conditional on observed covariates (eg, pancreatic gland texture, duct diameter, pathologic findings of disease). By conditioning on the treatment score, this study would replicate some of the characteristics of a randomized clinical trial. 20 Owing to the current absence of level 1 evidence evaluating RPD and open PD (OPD), this study applied a propensity score-matching approach in a multicenter setting to demonstrate that RPD is noninferior to OPD in terms of CR-POPF development. Secondary end points included cohort comparisons in terms of the occurrence of any complication, mild to moderate complications, severe complications, 90-day mortality, 30-day readmission, and duration of hospital stay.
Methods
This study was approved by the institutional review boards at the University of Pennsylvania and the University of Pittsburgh Medical Center. In the overall series, 51 pancreatic surgeons contributed PDs from 17 high-volume, academic institutions. All OPDs were performed at 16 22 Selection criteria for RPD, by those 3 surgeons, has expanded significantly beyond the learning curve, such that the only contraindications to RPD during this study period were (1) the inability to tolerate pneumoperitoneum, (2) borderline resectable tumors that require an end-to-end venous reconstruction or conduit, and (3) unavailability of the robot owing to scheduling limitations or lack of "block time." Within the study time period, a total 304 PDs were performed by the 3 surgeons at UPMC, of which 205 (67.4%) were approached robotically. All RPDs were performed in a standardized fashion. Following laparoscopic exploration, the robot was docked and used for the entire resection and reconstructive phases of the procedure. The PJs were performed in a duct-to-mucosa fashion using a modified Blumgart technique. Briefly, this end-to-side PJ involves an outer (ie, pancreatic capsule to seromuscular jejunum) layer of 3 horizontally placed inverted mattress silk sutures. The same suture is used to create both the anterior and posterior outer layer of the anastomosis. Each suture begins by traversing the pancreas in full-thickness from its anterior to posterior surface, followed by a seromuscular bite of the jejunum, and back again to traverse the pancreas in full thickness fashion from the posterior to the anterior surface. The sutures are tied, but the needles are kept in situ so they can be used again for the anterior layer. An interrupted duct-to-mucosa anastomosis is then performed using 6 sutures of 5-0 absorbable material (PDS or Vicryl) over an internal stent (Hobbs Medical Inc). Finally, the same silk needles used for the posterior layer are used to create the anterior layer. All PJs were drained by a single anterior 10-mm Blake drain, and early
Key Points
Question Is the use of robotic pancreatoduodenectomy (RPD) noninferior to open pancreatoduodenectomy (OPD) in terms of clinically relevant pancreatic fistula occurrence?
Findings In this propensity score-matched analysis of 304 patients, RPD demonstrated similar clinically relevant pancreatic fistula rates compared with OPD. Robotic pancreatoduodenectomy was also noninferior to OPD in terms of the occurrence of any complication, severe complications (Accordion severity grading system grade Ն3), hospital stay, 30-day readmission, and 90-day mortality.
Meaning Robotic pancreatoduodenectomy is noninferior to OPD in terms of clinically relevant pancreatic fistula development and other major postoperative outcomes.
drain removal (ie, on postoperative day 3 or 4) was used following serum and drain amylase measurements on postoperative day 3.
For both operative approaches, cases were included only if all 4 elements of the Fistula Risk Score (FRS), a validated risk assessment tool for CR-POPF, 23 were documented. In addition, the placement of intraoperative drains, transanastomotic stents, and somatostatin analogs (ie, octreotide) were made at the surgeon's discretion.
Pancreatic Fistula Classification
The primary outcome of interest was CR-POPF, which was graded in accordance with ISGPF standards. 13 Transient, biochemical (ie, grade A) leaks were not studied owing to their lack of clinical impact on outcomes. 24 Clinically relevant fistulas (ie, grades B and C) have clinically significant effects and significantly alter the patient's recovery. Grade B POPFs are often treated with therapeutic agents, such as antibiotics, prophylactic somatostatin analogs, total parenteral nutrition, percutaneous drain placement, or prolonged operative drainage (ie, >3 weeks). Grade C POPFs are characterized by organ failure, reoperation, or death.
13,15
Assigning Fistula Risk
Fistula risk was determined using the validated, 10-point FRS.
11,23
This established metric is based on the presence of certain risk factors for the development of CR-POPF: soft to normal pancreatic parenchyma, pathologic findings of high-risk disease (all pathologic abnormalities other than pancreatic ductal adenocarcinoma or pancreatitis), small pancreatic duct diameter, and elevated intraoperative blood loss. Individual scores are derived through the summation of each of the 4 weighted risk factors. Calculated scores are then discretized and assigned to 1 of 4 risk zones: (1) negligible risk, 0 points; (2) low risk, 1 to 2 points; (3) moderate risk, 3 to 6 points; or (4) high risk, 7 to 10 points.
Statistical Analysis
The study was designed to demonstrate noninferiority of RPD to OPD in terms of CR-POPF development. An overall CR-POPF rate of 15.0% was assumed for both groups, and the noninferiority margin was set at 10%. In addition, the α was set at .05 and β at .20, yielding a power of 80%. Therefore, to demonstrate that there is truly no difference between the standard (ie, OPD) and experimental (ie, RPD) treatment, then 316 patients would be required to be 80% sure that the upper limit of a 1-sided 95% CIor equivalently a 90% 2-sided CI-would exclude a difference in favor of the standard group of more than 10%.
25
Continuous variables are expressed as mean (SD) or median (interquartile range [IQR]), while categorical variables are presented as absolute numbers and percentages. For univariate comparisons, χ 2 analysis or Fisher exact tests were used to evaluate categorical variables; alternatively, continuous variables were analyzed using t test and Wilcoxon rank sum test for normally and nonnormally distributed data, respectively. Stepwise, backward logistic regression analysis identified covariates associated with the use of RPD (P ≤ .05 for entry; P > .10 for removal). Propensity score matching is a method used to minimize treatment selection bias when estimating causal treatment effects in nonrandomized studies. 20 "Control" (ie, OPD) and "case"
(ie, RPD) sets are matched on a set of variables that would otherwise confound comparisons between them. Once a matched sample has been formed, the treatment effect can be estimated by directly comparing outcomes (eg, CR-POPF) between control and case patients in the matched sample. 26 In the primary analysis (model 1), propensity scores were developed accounting for all factors significantly associated with either undergoing RPD or CR-POPF occurrence on logistic regression analysis. Accordingly, individual propensity scores were calculated through logistic regression modeling 20 based on the following 7 covariates: pancreatic gland texture, pancreatic duct diameter, intraoperative blood loss, pathologic findings of high-risk disease (pancreatic ductal adenocarcinoma or pancreatitis vs other), intraoperative drain placement, octreotide prophylaxis, and transanastomotic stent placement. The OPD and RPD patients were then paired 1:1 on these propensity scores using exact matching.
27
A standard caliper size of 0.2 × log [SD of the propensity score] was used. Standardized differences were estimated before and after matching to evaluate the balance of covariates; small absolute values (<0.1) indicate balance between treatment groups. A secondary propensity score-matched analysis (model 2) was conducted accounting only for factors significantly associated with undergoing RPD. In this analysis, individual propensity scores were calculated through logistic regression modeling based on the following covariates: pancreatic gland texture, pancreatic duct diameter, and transanastomotic stent placement. The OPD and RPD patients were once again paired 1:1 on propensity scores using exact matching. The caliper size and subsequent analyses used to compare cohorts were the same as those used for the initial model. Following 1:1 propensity score-matching, CR-POPF occurrence between matched OPD and RPD patients was examined by McNemar test. 20 Secondary end points included mild to moderate complications (modified Accordion severity grading system grade 1-2), severe complications (modified Accordion grade ≥3), and any complication (modified Accordion grade ≥1). 28 In congruence with CR-POPF follow-up, these were assessed out to 90 days following the index procedure. Other outcomes studied were duration of hospital stay, 30-day readmission, and 90-day mortality. All binary outcome comparisons between propensity score-matched OPD and RPD cohorts were carried out using McNemar test, while continuous outcomes used the paired t test or Wilcoxon rank-sum test. 20 P ≤ .05 was considered statistically significant; all tests were 2-sided. All statistical computations were performed using SPSS statistical software (version 21.0; IBM Corp) with propensity score matching performed using the SPSS extension program developed by Felix Thoemmes.
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Results
Factors Predicting Undergoing RPD
The overall cohort was 51.5% male, with a median age of 64 years (IQR, 56-72 years). Before propensity score matching, 2846 patients-185 in the RPD set (6.5%) and 2661 in the OPD set (93.5%)-met study criteria. Significantly different variables on univariate comparisons between RPD and OPD co- 
Predictors of CR-POPF Occurrence
The impact of undergoing RPD on CR-POPF development was examined in the unmatched cohort (2846) using logistic regression modeling. After adjusting for potential confounders, undergoing RPD was associated with a reduced risk for CR-POPF incidence (OR, 0.4 [95% CI, 0.2-0.7]; P = .002) relative to OPD ( 
Characteristics of Propensity Score-Matched Cohorts
To better control for confounding in the selection of undergoing RPD vs OPD, patients were matched 1:1 based on the likelihood of either undergoing RPD or factors associated with CR-POPF occurrence in the unmatched cohort 20 ( Table 2 ). The propensity score-matched cohort from the primary analysis (model 1) comprised 304 patients-152 in the RPD group (50.0%) and 152 in the OPD group (50.0%). Covariate differences between cohorts were compared before and after matching (Table 1) . Previously observed covariate imbalances between RPD and OPD cohorts with respect to pancreatic gland texture, pancreatic duct diameter, intraoperative blood loss, type of reconstruction, intraoperative drain placement, transanastomotic stent placement, and administration of octreotide prophylaxis were alleviated after matching. As such, matching was effective in reducing the absolute standardized difference to less than 10% for all covariates. In fact, exact matching was achieved for every patient ( 
Effect of Undergoing RPD on CR-POPF Occurrence in Propensity Score-Matched Cohorts (Model 1)
In the overall propensity score-matched cohort (model 1), 27 patients (8.9%) developed a CR-POPF (grade B, 7.9%; grade C, 1.0%). Comparisons of the RPD and OPD matched cohorts revealed no significant differences in CR-POPF occurrence (6.6% vs 11.2%; P = .23). Further comparisons, stratified by FRS risk zone, confirmed noninferiority of RPD to OPD in terms of CR-POPF incidence (Table 3 ). In addition, no differences were observed between matched cohorts in terms of grade B (RPD vs OPD: 6.6% vs 9.2%; P = .52) or grade C (RPD vs OPD: 0 vs 2.0%; P = .25) POPF development. 
Effect of Undergoing RPD on Outcomes in Propensity Score-Matched Cohorts (Model 2)
Outcomes were also compared between RPD (n = 171) and OPD (n = 171) matched cohorts from the secondary propensity scorematched analysis (model 2). Similar to results from model 1, there were no significant differences between RPD and OPD cohorts in terms of the development of CR-POPF (7.0% vs 12.3%; P = .10), grade B POPF (7.0% vs 9.9%; P = .33), or grade C POPF (0% vs 2.3%; P = .12). In addition, the RPD cohort had noninferior outcomes compared with the OPD cohort in terms of the occurrence of any complication (Accordion 
Discussion
This study demonstrates that RPD is noninferior to OPD for CR-POPF occurrence. To control more comprehensively for biases associated with the selection of a particular operative approach for PD, we stringently matched RPD and OPD patients using a propensity score-matching method. In matched patients, noninferiority of RPD was observed for CR-POPF occurrence. Secondary analyses also identified a similar incidence of any complication, mild to moderate complications, severe complications, readmission, mortality, and duration of hospital stay between RPD and OPD. The importance of a focused analysis comparing CR-POPF outcomes between RPD and OPD is manifold. First, CR-POPFs are the greatest contributor to major morbidity and mortality following PD 9-12 ; therefore, this complication is strongly associated with the overall incidence of severe complications, 11,12 duration of hospital stay, 11 readmission, 30 and mortality. 15 Second, the risk factors for this complication have been well defined, 9,11,23 which enabled the present study to match RPD and OPD patients on characteristics relevant to the outcome of interest-thus eliminating bias. The first study comparing CR-POPF outcomes between RPD and OPD showed equivalency between operative approaches.
17 Despite demonstrating similarities in CR-POPF outcomes and mortality, Zhou and colleagues 17 reported lower rates of overall complications and reduced hospital stay with RPD. Although the present study also showed similar rates of CR-POPF between cohorts following propensity score matching, the rates of overall complications and hospital stay were, instead, noninferior between RPD and OPD. Potential expla- 
Limitations
To our knowledge, this propensity score-matched analysis of RPD and OPD represents the largest study on the subject to date, but it has several limitations that warrant emphasis. First, the institutions included in this analysis are all high-volume, academic, pancreatic surgery specialty centers; consequently, our findings may not be generalizable to lower-volume, nonacademic centers. Second, this study is retrospective, and, although many cases were consecutive, this did not apply across all institutions because all components of the FRS were required for inclusion in the analysis. Third, all RPDs were performed by a highly skilled and experienced group of surgeons who had surpassed the RPD learning curve before contributing to the current study; therefore, these findings may not be generalizable to less experienced surgeons who have not surpassed the learning curve for RPD. Fourth, despite adjusting for baseline differences between RPD and OPD patients using a rigorous propensity score-matching approach, it is possible that unmeasured confounders were not accounted for, resulting in residual treatment selection bias. Finally, it was determined that each cohort would require 158 patients (316 total) to demonstrate noninferiority of RPD to OPD (power = 80%, α = .05), but only 152 patients were matched for each operative technique (304 total) in model 1. Therefore, the initial analysis was slightly underpowered; however, the secondary propensity score-matched analysis (model 2)-which matched patients only on factors associated with use of RPDwas sufficiently powered, with 171 patients in each cohort (342 total). Future prospective randomized clinical trials will be necessary to determine whether one approach is superior to the other; however, an adequately powered superiority trial would require a substantial number of patients. For example, to demonstrate a one-third decrease in CR-POPF incidence would require 1368 patients (684 per cohort).
With comparable perioperative outcomes to OPD, this study provides an impetus to continue exploring the potential benefits-or lack thereof-of RPD. In the current climate of value driven health care, the cost of using the robotic platform for complex procedures, such as PD, needs to be carefully examined. While this study focused on traditional perioperative outcome metrics, studies examining the impact of this platform on indirect costs including quality of life, receipt and completion of full-dose multidrug adjuvant chemotherapy-rather than time to adjuvant therapy-and survival are urgently needed. As such, this study adds to a growing body of evidence that dispels reports of inferior perioperative outcomes for minimally invasive PD, provided these procedures are performed by highvolume pancreatic surgeons in a systematic and structured setting, and lays the foundation for longitudinal patientcentered assessments of various approaches to PD.
Conclusions
To our knowledge, this study is the largest of its kind to compare the efficacy of robotic vs open PD, as well as the first to use propensity score-matching methodology. The findings herein demonstrate that robotic PD is noninferior to open PD in terms of pancreatic fistula development and other major postoperative outcomes. The results demonstrate that clinically relevant fistula rates, overall complications, length of hospital stay (LOS), mortality, and readmission rates were similar, suggesting that RPD is not inferior to OPD for these metrics.
The authors, from the University of Pittsburgh (UPMC), should be commended for their dedication to the advancement and reporting of RPD, which remains a technically challenging endeavor, 2 and for their work to define the learning curve and training curriculum. 2 As the authors acknowledge, there are limitations to this retrospective analysis, including patient selection bias, and the challenge of controlling for all of the confounding variables in the propensity scorematching approach. In this study, only cases from experienced surgeons that have surpassed the learning curve of 80 cases 2 were included, but pancreatic fistula rates during the early phase of the learning curve were as high as 27.5%. Unlike the benefits demonstrated in left-sided pancreatectomies, 3 minimally invasive PD has failed to consistently demonstrate significant improvements in outcomes, such as decreased LOS, quicker return to baseline activity, fewer complications, reduced mortality, and shorter time to adjuvant therapy. 4 A recent multi-institutional comparison of perioperative outcomes for RPD and OPD 5 demonstrated reduced operative blood loss without a decrease in transfusions, and perhaps a reduction in major complications for the RPD group, at the expense of substantially longer operative times with no LOS improvements. Although not measured, it is likely that RPD requires substantially increased costs to initiate the program and to establish the level of expertise attained at UPMC. These financial considerations warrant further investigation in this era of bundled payments, and increasing cost-value awareness. Given the extensive learning curve, and the definition that high-volume centers perform 10 resections per year, it seems improbable that even high-volume surgeons could extrapolate the findings of this study to their own practice-and ultimately for what benefit and at what cost? Although the authors demonstrate the safety of this approach with highly trained physicians at one high-volume center, the wide adaptability and impact of RPD remains in question. Technological innovation should improve standards of care, rather than settling for noninferiority. As experience and technology improve, RPD and OPD will both evolve, but better studies are needed to clarify by whom and where these innovations will be advanced. This study represents an early effort to address these questions by an accomplished group of surgeons who are paving the way.
